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Articles
Mortality and cardiovascular and respiratory morbidity in 
individuals with impaired FEV₁ (PURE): an international, 
community-based cohort study
MyLinh Duong, Shofiqul Islam, Sumathy Rangarajan, Darryl Leong, Om Kurmi, Koon Teo, Kieran Killian, Gilles Dagenais, Scott Lear, 
Andreas Wielgosz, Sanjeev Nair, Viswanathan Mohan, Prem Mony, Rajeev Gupta, Rajesh Kumar, Omar Rahman, Khalid Yusoff, 
Johannes Lodewykus du Plessis, Ehimario U Igumbor, Jephat Chifamba, Wei Li, Yin Lu, Fumin Zhi, Ruohua Yan, Romaina Iqbal, 
Noorhassim Ismail, Katarzyna Zatonska, Kubilay Karsidag, Annika Rosengren, Ahmad Bahonar, Afazalhussein Yusufali, Pablo M Lamelas, 
Alvaro Avezum, Patricio Lopez-Jaramillo, Fernando Lanas, Paul M O’Byrne, Salim Yusuf, on behalf of the PURE investigators
Summary
Background The associations between the extent of forced expiratory volume in 1 s (FEV₁) impairment and mortality, 
incident cardiovascular disease, and respiratory hospitalisations are unclear, and how these associations might vary 
across populations is unknown.
Methods In this international, community-based cohort study, we prospectively enrolled adults aged 35–70 years who 
had no intention of moving residences for 4 years from rural and urban communities across 17 countries. A portable 
spirometer was used to assess FEV₁. FEV₁ values were standardised within countries for height, age, and sex, and 
expressed as a percentage of the country-specific predicted FEV₁ value (FEV₁%). FEV₁% was categorised as no 
impairment (FEV₁% ≥0 SD from country-specific mean), mild impairment (FEV₁% <0 SD to –1 SD), moderate 
impairment (FEV₁% <–1 SD to –2 SDs), and severe impairment (FEV₁% <–2 SDs [ie, clinically abnormal range]). 
Follow-up was done every 3 years to collect information on mortality, cardiovascular disease outcomes (including 
myocardial infarction, stroke, sudden death, or congestive heart failure), and respiratory hospitalisations (from 
chronic obstructive pulmonary disease, asthma, pneumonia, tuberculosis, or other pulmonary conditions). Fully 
adjusted hazard ratios (HRs) were calculated by multilevel Cox regression.
Findings Among 126 359 adults with acceptable spirometry data available, during a median 7·8 years (IQR 5·6–9·5) of 
follow-up, 5488 (4·3%) deaths, 5734 (4·5%) cardiovascular disease events, and 1948 (1·5%) respiratory hospitalisation 
events occurred. Relative to the no impairment group, mild to severe FEV₁% impairments were associated with 
graded increases in mortality (HR 1·27 [95% CI 1·18–1·36] for mild, 1·74 [1·60–1·90] for moderate, and 2·54 
[2·26–2·86] for severe impairment), cardiovascular disease (1·18 [1·10–1·26], 1·39 [1·28–1·51], 2·02 [1·75–2·32]), 
and respiratory hospitalisation (1·39 [1·24–1·56], 2·02 [1·75–2·32], 2·97 [2·45–3·60]), and this pattern persisted in 
subgroup analyses considering country income level and various baseline risk factors. Population-attributable risk for 
mortality (adjusted for age, sex, and country income) from mildly to moderately reduced FEV₁% (24·7% [22·2–27·2]) 
was larger than that from severely reduced FEV₁% (3·7% [2·1–5·2]) and from tobacco use (19·7% [17·2–22·3]), 
previous cardiovascular disease (5·5% [4·5–6·5]), and hypertension (17·1% [14·6–19·6]). Population-attributable risk 
for cardiovascular disease from mildly to moderately reduced FEV₁ was 17·3% (14·8–19·7), second only to the 
contribution of hypertension (30·1% [27·6–32·5]).
Interpretation FEV₁ is an independent and generalisable predictor of mortality, cardiovascular disease, and respiratory 
hospitalisation, even across the clinically normal range (mild to moderate impairment).
Funding Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke 
Foundation of Ontario, Ontario Ministry of Health and Long-Term Care, AstraZeneca, Sanofi-Aventis, Boehringer 
Ingelheim, Servier, and GlaxoSmithKline, Novartis, and King Pharma. Additional funders are listed in the 
appendix.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
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Introduction
Many studies have shown the associations of reduced lung 
function with future risk of mortality, respiratory out­
come, and cardiovascular outcomes.1–4 In current practice, 
forced expiratory volume in 1 s (FEV₁) is considered to be 
abnormal when it is lower than –2 standard deviations 
(SDs) from the population mean for age, height, and sex.5 
However, there is little data on whether mild abnormalities 
in lung function, within clinically normal range, are 
associated with similar increases in poor health outcomes. 
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Furthermore, most evidence is from western popu lations in 
high­income countries, whereas less data and knowledge 
are available regarding these associations in middle­
income and low­income countries,6–8 where the scope of 
risk exposures, population susceptibility, and aetiological 
factors for lung function impairment are different.
The prospective urban rural epidemiology (PURE) 
study, is an international, community­based cohort study 
in which adults were enrolled from high­income, middle­
income, and low­income countries.9 As part of the study, 
we examined the associations between the extent of 
baseline FEV₁ impairment and future risks of mortality, 
cardiovascular disease events, and respiratory hos­
pitalisations, and analysed whether these associations 
vary by socioeconomic, geographical, demographic, and 
clinical background, with the aim of providing insights 
into the mechanisms underlying epidemiological links 
between lung function and cardiorespiratory outcomes.
Methods
Study design and participants
The methods of PURE have been previously published9 
and are summarised in the appendix (pp 5–9). Countries 
and centres were chosen to provide a wide range of 
socioeconomic and environmental settings, balanced by 
the feasibility of achieving high­quality data collection 
and long­term follow­up. 628 urban and rural 
communities from 17 countries (high­income, middle­
income, and low­income) were included. Stan dardised 
approaches were used for the enumeration of house­
holds, identification of individuals, recruitment, and data 
collection. Because collection of data from nationally 
representative samples in each country was not feasible, 
the sampling methods were carefully chosen to avoid 
biases in participant selection based on risk factors and 
disease prevalence.
Households with members aged 35–70 years who had 
no intention of moving residences for 4 years were 
eligible. The demographic and mortality statistics for 
PURE have been validated against each country’s 
national statistics and have shown good agreement 
(appendix p 8). The study is coordinated by the Popula­
tion Health Research Institute, McMaster University 
(Hamilton, ON, Canada); and approved by the Hamilton 
Health Sciences research ethics board and by each site’s 
ethics committee.
Research in context
Evidence before this study
We searched PubMed, Embase, and Cochrane databases and the 
bibliographies of retrieved papers for relevant publications in 
English between Jan 1, 1960, and July 1, 2018. We used key search 
terms ”lung function”, “lung capacity”, “ventilatory capacity”, 
“forced expiratory volume in 1 second (FEV₁)”, and “forced vital 
capacity” to identify reports of lung function and prospectively 
collected data on mortality and cardiovascular and respiratory 
events. A large body of evidence shows a strong epidemiological 
link between reduced lung function and elevated future risk of 
mortality and cardiorespiratory outcomes. The association 
extends to reduced lung function levels in early adulthood, 
indicating that it is independent of ageing. However, few data are 
available regarding populations outside of high-income 
countries, where the range of risk exposures, population 
susceptibility, and aetiological factors for lung function 
impairment are different. Therefore, the global implications and 
burden of impaired lung function, and how these aspects might 
vary across diverse populations, are unknown.
Added value of this study
In a prospective, international, community-based cohort 
study involving 126 359 adults from 628 urban and rural 
communities across 17 high-income, middle-income, 
and low-income countries, we observed significant and graded 
increases in rates and risks (standardised for age and sex) of 
mortality, cardiovascular disease events, and respiratory 
hospitalisations with decreasing FEV₁ values standardised by 
country-specific values (FEV₁%). The graded increases in adverse 
outcomes were significant even for mild reductions in FEV₁% 
that are commonly accepted as clinically normal (ie, between 
0 and –2 SDs below the population mean for age, height, 
and sex), as well as for abnormal levels (lower than –2 SD). 
FEV₁% reductions within the normal range showed higher 
population-attributable risk for mortality than did FEV₁% 
reductions in the abnormal range, and also contributed more to 
mortality than did tobacco use, previous cardiovascular disease, 
and hypertension. The population-attributable risk for incident 
cardiovascular disease from reduced FEV₁% was second only to 
the risk from hypertension, and was higher than that of previous 
cardiovascular disease and tobacco use. The exposure–outcome 
gradient was consistent across diverse populations from 
different country income levels and from rural or urban 
communities, and with different baseline risk levels.
Implications of all the available evidence
Reduced FEV₁ is a strong, independent, and highly generalisable 
predictor of mortality and cardiovascular disease and respiratory 
outcomes. The largest population burden is associated with 
mildly to moderately reduced FEV₁, commonly accepted as 
being within the normal limits for age, height, and sex. 
Impaired lung function is a stronger risk factor for mortality and 
cardiovascular disease events than are most currently accepted 
conventional risk factors, accounting for one in four deaths and 
one in six cardiovascular disease events. Reducing the burden of 
impaired FEV₁, particularly in the mild to moderate range, 
could have a substantial impact in decreasing mortality and 
cardiorespiratory morbidity. The highly consistent and 
continuous graded exposure–outcome relationship observed 
across populations with diverse risk exposures and susceptibility 
strongly supports the notion of direct causal relationships 
between reduced lung function and health outcomes.
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Procedures
Standardised, interview­based questionnaires were 
administered to household members aged 35–70 years 
to elicit information on demographics and house­
hold, medical, and risk factors (appendix p 10). 
Standardised measurements of anthropometrics, blood 
pressure, hand grip strength, and spirometry were 
taken. Lung function was measured with a portable 
spirometer (MicroGP; MicroMedical, Chatham, IL, 
USA), without spirographs, with use of a standard­
ised protocol. Participants were coached before 
attempting pre­bronchodilator forced expiratory 
manoeuvres (maximum six attempts) while standing 
and wearing a nose­clip. Manoeuvres were observed to 
ensure maximal effort, forced exhalation time of at least 
6 s, and exhalation without coughing. Participants with 
two or more FEV₁ and forced vital capacity (FVC) 
measurements within 200 mL variability were selected. 
The highest FEV₁ values per patient were analysed. 
The quality of spirometry data has previously 
been validated and shown strong agreement with 
FEV₁ values acquired at hospital­based pulmonary 









FEV₁% 112·9 (106–122) 91·5 (86–96) 70·7 (64–75·4) 46·9 (35·4–53)
FVC% 111·3 (102–122) 90·1 (82·5–98·5) 71·7 (63·3–83·8) 53·4 (41·7–70·4)
FEV₁/FVC
Median (IQR) 0·87 (0·8–0·9) 0·86 (0·8–0·9) 0·83 (0·7–0·9) 0·72 (0·6–0·9)
<0·70 1773 (2·7%) 3523 (8·5%) 3272 (23·0%) 1843 (45·0%)
Sex
Female 38 303 (57·6%) 24 770 (59·7%) 8418 (59·1%) 2028 (49·5%)
Male 28 210 (42·4%) 16 738 (40·3%) 5827 (40·9%) 2065 (50·5%)
Location
Urban 35 584 (53·5%) 22 799 (54·9%) 7024 (49·3%) 1932 (47·2%)
Rural 30 929 (46·5%) 18 706 (45·1%) 7221 (50·7%) 2161 (52·8%)
Age, years 50 (42–58) 50 (42–58) 52 (43–60) 53 (44–62)
Body-mass index, kg/m2
Median (IQR) 25·2 (22·5–28·3) 25·4 (22·4–28·8) 25·3 (22·1–28·9) 24·9 (21·8–28·3)
<18·5 2678 (4·0%) 2078 (5·0%) 902 (6·3%) 294 (7·2%)
Primary or no education 26 414 (39·7%) 16 839 (40·6%) 6890 (48·4%) 2034 (49·7%) 
Tobacco use
Former (last use ≥12 months ago) 8237 (12·4%) 4638 (11·2%) 1547 (10·9%) 588 (14·4%) 
Current (last use <12 months ago) 13 188 (19·8%) 8691 (20·9%) 3369 (23·7%) 1064 (26·0%)
Never 44 627 (67·1%) 27 819 (67·0%) 9190 (64·5%) 2398 (58·6%)
Solid fuel for cooking 17 402/65 176 (26·7%) 10 138/40 552 (25·0%) 3701/13 861 (26·7%) 1335/3997 (33·4%)
Handgrip strength, kg 29·3 (22·7–38) 27·7 (21–36) 26·7 (20–34) 28 (20·7–36·7)
Low physical activity* 9648/61 846 (15·6%) 6467/38 958 (16·6%) 2437/13 317 (18·3%) 855/3851 (22·2%)
Alternative healthy eating score† 34·8 (29·5–40·2) 34·8 (29·3–40·3) 34·8 (29·2–40·2) 34·1 (28·3–39·7)
Cardiorespiratory symptoms‡ 19 152 (28·8%) 13 495 (32·5%) 5435 (38·2%) 1858 (45·4%)
Inhaler therapy 766 (1·2%) 789 (1·9%) 522 (3·7%) 351 (8·6%)
Hypertension§ 14 614 (22·0%) 10 561 (25·4%) 4141 (29·1%) 1229 (30%)
Chronic respiratory disease¶ 1973 (3·0%) 2032 (4·9%) 1255 (8·8%) 724 (17·7%)
Diabetes|| 6022 (9·1%) 4629 (11·2%) 1731 (12·2%) 502 (12·3%)
Cardiovascular disease** 2973 (4·5%) 2294 (5·5%) 1011 (7·1%) 371 (9·1%)
Cancers†† 1019 (1·5%) 770 (1·9%) 294 (2·1%) 110 (2·7%)
Data are n (%) or median (IQR). FEV₁% and FVC% are FEV₁ and FVC values standardised as a percentage of country-specific predicted values. FEV₁=forced expiratory volume in 
1 s. FVC=forced vital capacity. *Defined as <600 metabolic equivalents per min per week from the International Physical Activity Questionnaire. †Scores range from 6–70, 
with higher scores indicating a more healthy diet. ‡Self-reported symptoms of wheeze, cough, sputum, chest-pain, or breathlessness with usual activity occurring at least 
weekly within 6 months of baseline questionnaire. §Blood pressure >140/90 mm Hg at baseline visit or a history of hypertension with regular antihypertensive medications. 
¶Self-reported history of physician-diagnosed chronic respiratory disease (chronic obstructive pulmonary disorder, tuberculosis, or asthma). ||Self-reported history of 
physician-diagnosed diabetes. **Self-reported history of physician-diagnosed cardiovascular disease (include any heart conditions, cerebrovascular disease, or peripheral 
vascular disease). ††Self-reported history of physician-diagnosed cancer, including all cancer types except for non-melanoma skin cancers.
Table 1: Baseline characteristics by country-standardised FEV₁% category
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laboratories from 531 participants (mean differences 
6–161 mL) across sites.10
To ensure standardisation and collection of high­quality 
data, comprehensive operation manuals, regular training 
workshops, DVDs, and feedback were made available. 
Data were entered locally into customised databases with 
ranges and consistency checks, and transmitted centrally 
for further quality control.
Follow­up for new events related to the outcomes of 
interest was done every 3 years, with information 
collected from participants or (if the patient had died) 
from close relatives (verbal autopsies).11 All supporting 
documentation was retrieved and locally adjudicated by 
trained physicians with use of standardised definitions 
(appendix pp 11–14). All fatal events and a random subset 
of non­fatal events were regularly selected for central 
adjudication to check for consistency across sites.
Because current reference values do not sufficiently 
cover the scope of ethnic and geographical regions 
represented in PURE, measured FEV₁ values were 
internally standardised within each country. An allome­
tric10 equation previously derived and validated in PURE 
was used to regress FEV₁ to height, age, and sex on all 
acceptable spirometry data stratified by country. The 
resultant regression models generated country­specific 
predicted FEV₁ values. Measured FEV₁ values were 
standardised as a percentage of country­specific predicted 
FEV₁ (ie, FEV₁%=FEV₁ ÷ predicted FEV₁ × 100), which 
compared participants’ FEV₁ values to their respective 
country mean FEV₁ for individuals of that height, age, 
and sex. The resultant country­standardised FEV₁%s 
were normally distributed, centring (mean) on 100% 
with SDs, which varied by country (appendix p 15). 
Country­specific SDs were used to standardise FEV₁% 
impairment across countries into four categories: no 
impairment (FEV₁% ≥0 SD from population mean), mild 
im pairment (FEV₁% <0 SD to –1 SD from population 
mean), moderate impairment (FEV₁% <–1 SD to –2 SD 
from population mean), and severe impairment 
(FEV₁% <–2 SD from population mean [ie, clinically 
abnormal range]). We also did further analyses of the 
effects of FVC%, standardised by country and categorised 
into four groups (no impairment, mild impairment, 
moderate impairment, and severe impairment) on the 
basis of country­specific SDs, as was done for FEV₁%. 
In addition, we compared our findings to results from 
similar analyses using the Global Lung Initiative (GLI) 
predictive values12 to express measured FEV₁.
Outcomes
The outcomes examined were death (excluding deaths 
due to injuries), cardiovascular disease (myocardial 
infarction, stroke, sudden death, or congestive heart 
failure), and admission to hospital for respiratory reasons 
(from chronic obstructive pulmonary disease, asthma, 
pneumonia, tuberculosis, or other pulmonary conditions) 
in relation to FEV₁% category.
Statistical analysis
The associations between FEV₁% and the specified 
outcomes were examined with use of multilevel Cox 
models, treating centres as random effects. Hazard ratios 
(HRs), with the no impairment group used as the 
reference, were adjusted for age (continuous); sex; country 
income (high, middle, or low); urban or rural community; 
body­mass index (<20 kg/m², 20 to <30 kg/m², or 
≥30 kg/m²); education (up to primary level, secondary 
level, or trade, college, or university level); cooking fuel 
use (electricity or gas, or solid fuel); tobacco use (ever or 
never); alcohol use (ever or never); inhaled medication 
use; hypertension (defined as self­reported hypertension 
with anti­hypertensive medic ations or measured blood 
Figure 1: Incidence of death and cardiovascular and respiratory outcomes by baseline country-standardised FEV₁% impairment category
Incidence was standardised for age and sex. All deaths includes deaths from any cause except injury. Cardiovascular disease includes myocardial infarction, congestive 
heart failure, stroke, sudden death, and deaths due to cardiovascular disease. Respiratory hospitalisations include those due to chronic obstructive pulmonary disease, 
asthma, tuberculosis, pneumonia, or other ICD-10 respiratory conditions, but exclude deaths due to respiratory conditions. Full data are provided in table 2. 











































FEV1% No impairment Mild impairment Moderate impairment Severe impairment
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pressure >140/90 mm Hg); known cardiovascular diseases 
(all cardiac conditions, strokes, peripheral vasc ular dis­
ease), chronic respiratory diseases (chronic obstructive 
pulmonary disease, asthma, tuberculosis, or other 
pulmonary diseases), cancers (excluding non­melanoma 
skin cancers), HIV infection, or diabetes; physical activity 
(low, moderate, or high) on the International Physical 
Activity Questionnaire;13 dietary pattern (healthy eating 
score14); and handgrip strength. The proportional hazards 
assumption was checked by visual inspection of log–log 
plots. Population­attributable risk was calculated with use 
of the SAS Macro15 based on the Cox model, adjusted for 
age, sex, and country income level.
Separate stratified analyses were done for country­
income (high vs middle vs low [World Bank 2006 
Classification]); urban versus rural community; tobacco 
use (ever vs never [self­reported use of zero tobacco 
products per day and zero days of use per year]); age 
(<50 years vs 50–65 years vs >65 years); cooking fuel 
use (gas or electricity vs solid fuel); healthy (no history 
of tobacco or alcohol use, cardiorespiratory symp­
toms, cardiovascular disease, Chagas disease, chronic 
respiratory disease, cancers, HIV infection, hypertension, 
diabetes, malaria, tuberculosis, hepatitis, or pregnancy) 
versus not healthy status; and baseline self­reported 
cardiorespiratory status (no known cardiovascular 









Number of events 2187 (3·3%) 1838 (4·4%) 1005 (7·1%) 458 (11·2%)
HR (95% CI) versus no impairment group 1 (ref) 1·27 (1·18–1·36) 1·74 (1·60–1·90) 2·54 (2·26–2·86)
HR (95% CI) versus adjacent group ·· ·· 1·38 (1·26–1·50)* 1·46 (1·28–1·65)†
Cardiovascular disease deaths
Number of events 654 (1·0%) 556 (1·3%) 341 (2·4%) 156 (3·8%)
HR (95% CI) versus no impairment group 1 (ref) 1·32 (1·16–1·50) 1·92 (1·65–22·3) 2·77 (2·26–3·40)
HR (95% CI) versus adjacent group ·· ·· 1·46 (1·25–1·70)* 1·44 (1·16–1·79)†
Respiratory deaths
Number of events 89 (0·1%) 65 (0·2%) 64 (0·4%) 74 (1·8%)
HR (95% CI) versus no impairment group 1 (ref) 1·22 (0·85–1·76) 2·53 (1·72–3·74) 8·06 (5·43–12·0)
HR (95% CI) versus adjacent group ·· ·· 2·08 (1·39–3·11)* 3·18 (2·12–4·77)†
Cardiovascular disease
Number of events 2522 (3·8%) 1937 (4·7%) 926 (6·5%) 349 (8·5%)
HR (95% CI) versus no impairment group 1 (ref) 1·18 (1·10–1·26) 1·39 (1·28–1·51) 2·02 (1·75–2·32)
HR (95% CI) versus adjacent group ·· ·· 1·18 (1·08–1·29)* 1·27 (1·11–1·46)†
Myocardial infarction
Number of events 1038 (1·6%) 813 (2·0%) 402 (2·8%) 164 (4·0%)
HR (95% CI) versus no impairment group 1 (ref) 1·16 (1·05–1·28) 1·43 (1·26–1·63) 1·95 (1·61–2·36)
HR (95% CI) versus adjacent group ·· ·· 1·23 (1·08–1·40)* 1·37 (1·11–1·68)†
Stroke
Number of events 1318 (2%) 927 (2·2%) 412 (2·9%) 123 (3·0%)
HR (95% CI) versus no impairment group 1 (ref) 1·09 (0·99–1·19) 1·22 (1·08–1·37) 1·20 (0·97–1·48)
HR (95% CI) versus adjacent group ·· ·· 1·12 (0·99–1·27)* 0·99 (0·79–1·24)†
Congestive heart failure
Number of events 229 (0·3%) 202 (0·5%) 122 (0·9%) 47 (1·1%)
HR (95% CI) versus no impairment group 1 (ref) 1·45 (1·18–1·78) 2·09 (1·64–2·66) 2·56 (1·80–3·64)
HR (95% CI) versus adjacent group ·· ·· 1·44 (1·13–1·84)* 1·23 (0·85–1·77)†
Respiratory hospitalisation
Number of events 751 (1·1%) 663 (1·6%) 365 (2·6%) 169 (4·1%)
HR (95% CI) versus no impairment group 1 (ref) 1·39 (1·24–1·56) 2·02 (1·75–2·32) 2·97 (2·45–3·60)
HR (95% CI) versus adjacent group ·· ·· 1·45 (1·26–1·67)* 1·47 (1·20–1·80)†
Frequency data are n (% from total participants within impairment category). HRs referenced to the no impairment group were estimated with a multilevel Cox proportional 
hazards model adjusted for age, sex, urban or rural community, body-mass index, handgrip strength, educational level, cooking fuel, country income level, tobacco use 
status, alcohol use status, self-reported diabetes or cardiorespiratory disease or HIV infection, hypertension, inhaler therapy, physical activity, dietary pattern, and centres as 
random effects. HRs referenced to next most severe impairment group (ie, moderate vs mild, severe vs moderate) were calculated with use of similar fully adjusted mixed 
effects Cox models. HR=hazard ratio. *Referenced to mild impairment group. †Referenced to moderate impairment group.
Table 2: Number of events and adjusted HRs by country-standardised FEV₁% impairment category
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disease, chronic respiratory disease, or current respi­
ratory symptoms [no self­reported wheeze, cough, 
sputum, or breathlessness with usual activity occurring 
at least weekly in the past 6 months] vs current respiratory 
symptoms only vs known chronic respiratory disease 
only vs known cardiovascular disease).
With the same multilevel Cox regression method, 
we also compared each category against the previous (less 
impaired) category to assess the incremental increases in 
HR between one FEV₁% category and the next. HRs were 
plotted to examine for potential interactions between 
strata with FEV₁%. Given the multiple comparisons, 
nominally significant p values should be interpreted 
cautiously, unless very small (p<0·001) or the results 
form a coherent pattern. All analyses were done in SAS 
version 9.4.
Role of the funding source
The funders and sponsors had no role in the design and 
conduct of the study; in the collection, analysis, and 
interpretation of the data; in the preparation, review, or 
approval of the manuscript; or in the decision to submit 
the manuscript for publication.
Results
Of the 164 162 participants enrolled in the PURE study 
between Jan 1, 2005, and March 29, 2017, 126 359 had 
acceptable spirometry data (appendix p 16). Baseline data 
were collected from Jan 1, 2005, to Dec 30, 2009, and 
baseline characteristics of participants in the different 
FEV₁% categories are shown in table 1. 14 700 (11·6%) of 
participants were enrolled from high­income countries, 
89 926 (71·2%) from middle­income countries, and 
21 733 (17·2%) from low­income countries.
Follow­up was done from Jan 1, 2008, to Dec 30, 2013, 
and was complete for 157 267 (95·8%) participants. During 
a median follow­up period of 7·8 years (IQR 5·6–9·5), 
5488 (4·3%) of participants died, 5734 (4·5%) had cardio­
vascular disease events, and 1948 (1·5%) had respiratory 
hospitalisation. Mortality and incidence of cardiovascular 
disease events (standardised for age and sex) showed 
graded increases with decreasing FEV₁% (figure 1), and 
Cox analyses showed significant incremental increases 
in risk with each level of FEV₁ impairment (table 2), 
indicating a dose­response relation ship that was contin­
uous throughout all levels of impairment (appendix p 17). 
Although HRs were modest in the groups with mild or 
moderate impairment in FEV₁% (within the clinically 
normal range), the absolute numbers of events showed a 
high burden of disease in these groups. By contrast, the 
severely reduced FEV₁% group (in the clinically abnormal 
range) had the highest risk but accounted for a low 
proportion of events (458 [8·3%] of 5488 deaths, and 
156 [6·1%] 5734 cardiovascular disease events).
The population­attributable risk for mortality from 
mildly to moderately impaired (clinically normal) FEV₁% 
(24·7% [95% CI 22·2–27·2]) was more than six times 
higher than that from severely impaired (clinically 
abnormal) FEV₁% (3·7% [2·1–5·2]; table 3, appendix p 18), 
and was higher than the population­attributable risks from 
tobacco use, solid fuel cooking, previous cardio vascular 
disease, and hypertension. Similarly, the population­
attributable risk for incident cardiovascular disease from 
mildly to moderately impaired FEV₁% (17·3% [14·8–19·7]) 
was two times higher than that from severely impaired 
FEV₁% (7·5% [5·1–10·0]), and was higher than that 
the population­attributable risks from previous cardio­
vascular disease, tobacco use, and solid fuel cooking, but 
lower than that of hypertension (table 3). The population­
attributable risk for mortality from mildly to moderately 
impaired FEV₁% was consistently higher than that of 
hypertension across all FEV₁% levels and systolic blood 
pressure levels standardised within the population.
Severity of FEV₁% impairment was also associated 
with graded increases in risk of myocardial infarction, 
congestive heart failure, stroke, cardiovascular disease 
deaths, and respiratory deaths (table 2). Dose­response 
relationship with mortality was consistent across popu­
lations from different country income levels, rural and 
urban communities, tobacco use status, age, cooking 
fuel, and baseline cardiorespiratory morbidity status 
(figure 2, table 4). The effect of reduced FEV₁% on 
mortality was independent and additive to the increased 
mortality associated with old age (>65 years), low­income 
country residence, rural setting, tobacco use, solid­fuel 
cooking, and known cardiovascular disease at baseline. 
In the absence of FEV₁% impairment, stan dardised 
mortality incidence was similar among those with self­
reported respiratory symptoms or physician­diagnosed 
chronic respiratory disease alone and those without any 




risk for cardiovascular 
disease
Mild to moderate FEV₁ impairment 
(0 SDs to –2 SDs below population mean)
24·7% (22·2–27·2) 17·3% (14·8–19·7)
Severe FEV₁ impairment (lower than –2 SD below 
population mean)
3·7% (2·1–5·2) 7·5% (5·1–10·0)
Tobacco use 19·7% (17·2–22·3) 7·5% (5·2–9·9)
Previous cardiovascular disease 5·5% (4·5–6·5) 12·2% (11·0–13·4)
Hypertension 17·1% (14·6–19·6) 30·1% (27·6–32·5)
Solid fuel for cooking (all countries) 12·8% (10·6–15·0) 7·3% (5·3–9·2)
Solid fuel for cooking (low-income countries only) 19·7% (15·1–24·2) 12·7% (7·0–18·2)
FEV₁ below 50th percentile 25·5% (23·0–28·0) 18·2% (15·7–20·8)
Systolic blood pressure above 50th percentile 12·2% (8·9–15·5) 33·3% (30·2–36·2)
FEV₁ below 20th percentile 15·6% (14·0–17·2) 10·6% (9·0–12·1)
Systolic blood pressure above 80th percentile 12·1% (10·1–14) 22·6% (20·6–24·7)
FEV₁ below 5th percentile 7·1% (6·1–8·1) 3·7% (2·9–4·5)
Systolic blood pressure above 95th percentile 6·2% (5·1–7·2) 9·7% (8·6–10·9)
Population-attributable risks (% [95% CI]) were based on a Cox model, adjusted for age, sex, and country income level. 
FEV₁ and systolic blood pressure were standardised within each population. FEV₁=forced expiratory volume at 1 s.
Table 3: Population-attributable risks for death and cardiovascular disease from different major risk factors
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or severe FEV₁% impairment had a greater effect on 
mortality risk in the presence of cardiorespiratory 
symptoms or chronic respiratory disease than in their 
absence (table 4, appendix pp 19–20). Severe FEV₁% 
impairment had the greatest effect on mortality in the 
youngest subgroup (<50 years). A pattern of increasing 
mortality risk with decreasing FEV₁% was observed 
across most geographical regions and also in healthy 
individuals (appendix pp 22–23).
Impaired FEV₁% was also associated with respiratory 
deaths and hospitalisations (table 4), and risk of respi ratory 
events was especially high in the group with severe 
(clinically abnormal) impairments in FEV₁%. Even so, the 
absolute number of respiratory events (including deaths 
and hospitalisations) in the groups with mildly to 
moderately reduced FEV₁ was more than double the 
number in the group with severely reduced FEV₁%.
In sensitivity analyses, the addition of the 7476 par ticipants 
who had been removed because of spirometry data of 
suboptimal quality, adjustment for wealth index and 
other socioeconomic indicators, and removal of partici­
pants with obstructive impairment (FEV₁/FVC ratio 
Figure 2: Incidence of mortality by country-standardised FEV₁% impairment, stratified by subpopulation
Incidence was standardised for age and sex. Error bars are 95% CIs. Baseline cardiorespiratory morbidity was defined as none (no symptoms and no known 
cardiorespiratory disease), symptoms (cardiorespiratory symptoms only, without any known cardiorespiratory disease), chronic respiratory disease only, 
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<0·70) or restrictive impairment (country­standardised 
FVC% <–2 SDs from population mean) did not mean­
ingfully alter the effect of FEV₁% impairment on mortality 
observed in our primary analyses (appendix p 24).
The analysis of the associations between country­
standardised FVC% and death (due to all causes, excluding 
injury), respiratory deaths, cardiovascular disease events, 
and respiratory hospitalisations yielded similar findings to 
those of the FEV₁% analysis, showing increasing risk of 
these events with worsening FVC% (appendix p 25).
Finally, when FEV₁ values were standardised to GLI 
predicted values12 rather than PURE country­specific 
predicted values, we found similar exposure–outcome 
gradients for mortality, cardiovascular disease, and 
respiratory hospitalisations. However, PURE country­
standardised FEV₁ values showed stronger associations 
with risk of these events (ie, steeper gradients when HRs 
were plotted against impairment category) than those of 
the GLI­standardised FEV₁ values, suggesting better 
prediction of outcomes with PURE country­specific 
standardisation (appendix p 26).
Discussion
This large, international, community­based, prospective 
study involving 126 359 adults from 628 urban and rural 
communities in 17 countries yielded three main findings. 
First, we observed significant and graded relationships 
between decreasing baseline FEV₁% and increasing 
risks of mortality, cardiovascular disease, and respiratory 
events. The exposure–outcome gradients were con tinuous 
throughout all levels of FEV₁% impairment, whether or 
not impairment was defined as clinically normal or 
abnormal by current standards of practice.5 Second, the 
population­attributable risks for mortality and incident 
cardiovascular disease from impaired FEV₁ were high, 
contributing to around a quarter of deaths and a sixth of 
cardiovascular disease events. These contributions were 
higher than those of other major risk factors such as 
hypertension, previous cardiovascular disease, tobacco 
use, and solid fuel cooking. Furthermore, the contribution 
of mildly to moderately impaired FEV₁% (within the 
clinically normal range) was several times larger than that 
of severe FEV₁% impairment (in the abnormal range), 
suggesting that only a small subset of individuals on the 
risk continuums for death or cardiovascular disease have 
severe FEV₁% impairment. Third, the increased risk of 
mortality in individuals with FEV₁% impairment was 
consistent across populations from diverse socioeconomic, 
geographical, demographic, and clinical backgrounds. 
The effect of reduced FEV₁% was independent and 
No impairment Mild impairment Moderate impairment Severe impairment
Deaths HR (95% CI) Deaths HR (95% CI) Deaths HR (95% CI) Deaths HR (95% CI)
Country income
High 112/7679 (1·5%) 1 (ref) 122/4914 (2·5%) 1·48 (1·12–1·95) 67/1653 (4·1%) 2·00 (1·44–2·78) 38/454 (8·4%) 2·85 (1·88–4·32)
Middle 1398/47 827 (2·9%) 1 (ref) 1089/29 054 (3·7%) 1·23 (1·13–1·35) 609/9974 (6·1%) 1·71 (1·53–1·90) 288/3071 (9·4%) 2·38 (2·06–2·75)
Low 677/11 007 (6·2%) 1 (ref) 627/7540 (8·3%) 1·28 (1·12–1·46) 329/2618 (12·6%) 1·73 (1·47–2·03) 132/568 (23·2%) 2·73 (2·14–3·48)
Age, years
≤50 465/31 476 (1·5%) 1 (ref) 396/19 965 (2·0%) 1·21 (1·03–1·43) 143/6060 (2·4%) 1·32 (1·04–1·67) 62/1621 (3·8%) 2·79 (2·03–3·85)
50–65 1203/30 033 (4·0%) 1 (ref) 1043/18 234 (5·7%) 1·37 (1·25–1·50) 595/6774 (8·8%) 1·90 (1·70–2·13) 275/1950 (14·1%) 2·68 (2·30–3·13)
>65 519/5004 (10·4%) 1 (ref) 399/3309 (12·1%) 1·09 (0·94–1·27) 267/1411 (18·9%) 1·64 (1·39–1·95) 121/522 (23·2%) 2·12 (1·68–2·67)
Community
Urban 841/35 584 (2·4%) 1 (ref) 736/22 799 (3·2%) 1·21 (1·08–1·35) 389/7024 (5·5%) 1·70 (1·48–1·95) 166/1932 (8·6%) 2·56 (2·11–3·12)
Rural 1345/30 929 (4·3%) 1 (ref) 1102/18 709 (5·9%) 1·30 (1·19–1·43) 616/7221 (8·5%) 1·76 (1·58–1·97) 292/2161 (13·5%) 2·53 (2·17–2·94)
Cooking fuel
Gas or electricity 1259/48 356 (2·6%) 1 (ref) 1071/30 785 (3·5%) 1·22 (1·12–1·34) 600/10 296 (5·8%) 1·71 (1·53–1·92) 284/2691 (10·6%) 2·56 (2·20–2·97)
Solid fuel 928/17 977 (5·2%) 1 (ref) 767/10 591 (7·2%) 1·33 (1·19–1·48) 405/3915 (10·3%) 1·74 (1·52–1·99) 174/1388 (12·5%) 2·59 (2·14–3·13)
Tobacco use
Never 1168/44 627 (2·6%) 1 (ref) 920/27 819 (3·3%) 1·23 (1·11–1·35) 492/9190 (5·4%) 1·68 (1·49–1·90) 196/2398 (8·2%) 2·58 (2·16–3·08)
Ever 1002/21 425 (4·7%) 1 (ref) 909/13 329 (6·8%) 1·30 (1·18–1·44) 507/4916 (10·3%) 1·78 (1·58–2·02) 262/1652 (15·9%) 2·49 (2·12–2·93)
Baseline cardiorespiratory symptoms and diseases
None 1257/45 276 (2·8%) 1 (ref) 951/26 557 (3·6%) 1·26 (1·14–1·39) 418/8194 (5·1%) 1·59 (1·40–1·81) 138/1997 (6·9%) 2·13 (1·74–2·61)
Cardiorespiratory 
symptoms only
643/16 554 (3·9%) 1 (ref) 581/10 940 (5·3%) 1·25 (1·10–1·42) 328/3955 (8·3%) 1·83 (1·56–2·14) 159/1113 (14·3%) 2·84 (2·31–3·49)
Chronic respiratory 
disease
63/1710 (3·7%) 1 (ref) 83/1717 (4·8%) 1·11 (0·76–1·63) 112/1085 (10·3%) 2·25 (1·57–3·24) 98/612 (16·0%) 3·38 (2·32–4·93)
Cardiovascular disease 224/2973 (7·5%) 1 (ref) 223/2294 (9·7%) 1·38 (1·12–1·69) 147/1011 (14·5%) 1·75 (1·38–2·21) 63/371 (17·0%) 2·04 (1·49–2·80)
Mortality data are n/N (%) for each group and stratum. HRs were estimated with multilevel Cox proportional hazards models adjusted for demographic, socioeconomic, and clinical covariates, with centres as 
random effects within strata. See appendix for plots of HRs within strata by FEV₁% category.
Table 4: Number of deaths and HR for stratified models
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additive to the elevated risk of mortality from low­income 
country, rural community, older age, tobacco use, and 
known cardiovascular disease. However, the effect of 
reduced FEV₁% was multiplicative when associated with 
respiratory symptoms, known chronic respiratory disease, 
and younger age (<50 years), where it has larger prognos­
tic implications. The consistency of the dose–response 
relationship across populations of diverse risk exposures, 
susceptibility, and underlying aetiological factors for 
lung function impairment strongly suggests a direct 
causal relationship between reduced lung function and 
cardiorespiratory health outcomes.
The associations between reduced lung function 
(including FEV₁ and FVC reductions6,16) and future risk 
of mortality or cardiovascular disease have long been 
recognised, but mainly in high­income countries.1–4,17,18 
Reduced lung function has also been associated with 
comorbidities including diabetes,19 renal dysfunction,20 
and neurocognitive disease.21 Some of these associations 
have been recognised for minor impairments in lung 
function during early adulthood,22,23 which have remained 
significant for decades during follow­up,24 suggesting that 
they are unrelated to ageing or reverse causality. Reduced 
lung function might share similar trajectories and 
early developmental pathways with many of the chronic 
comorbidities associated with increased risk of mortality. 
Contributing to this field of research, our findings show 
that the association between lung function and mortality 
is robust and generalisable across populations from 
diverse country income levels, geographical regions, and 
communities, and in individuals with and without 
tobacco use or known cardiorespiratory disease. Even 
after adjusting for well known risk factors, reduced 
FEV₁% remained significant in predicting mortality and 
cardiovascular disease events, including myocardial 
infarction, stroke, congestive heart failure, and death due 
to cardiovascular disease. The reasons for the associations 
between reduced lung function and the many diverse 
disease outcomes are unknown. In chronic obstructive 
pulmonary disease, which has been associated with 
various extrapulmonary comorbidities and is increasingly 
being considered to be a multisystem disease,25 postulated 
mechanisms for these associations include common or 
shared risk factors (such as cigarette smoking) between 
the conditions, or a direct effect from the lungs (such as 
inflammation in the lungs causing reduced lung function 
as well as systemic effects on other organs or systems). 
In our sensitivity analyses, removing participants with 
obstructive (and restrictive) impairment, these associa­
tions remained unchanged. We speculate that reduced 
FEV₁% might be an important indicator of frailty or 
inherent susceptibility to developing chronic diseases. 
Alternatively, reduced FEV₁% might be causally related 
to systemic (inflam matory) pathways with multiorgan 
effects. Understanding such pathophysiological links 
could lead to novel and targeted approaches to prevent 
and reduce the burden of multiple diseases, including 
cardiovascular and respir atory diseases, as well as to 
reduce mortality.
Consistent with the scarce existing data,2 we found a 
graded relationship between declining FEV₁% (throughout 
clinically normal and abnormal ranges) and increasing 
risk of adverse outcomes. The absolute numbers of events 
were higher in the groups with mildly or moderately 
reduced FEV₁% than in with severely reduced FEV₁%. 
Therefore, the use of fixed thresholds (such as <–2 SD 
from population mean) to define lung function im­
pairment might substantially underestimate the adverse 
effects of reduced lung function on health. This 
relationship is analogous to the continuous associations 
between blood pressure or LDL cholesterol with 
cardiovascular disease,26,27 and suggests that approaches to 
improving lung function in those with mildly to moderately 
reduced FEV₁ could have a large impact on the burden of 
both respiratory and cardiovascular diseases.
The population­attributable risk for mortality from 
reduced FEV₁% was higher than the risks contributed 
by several major risk factors, including tobacco use, 
hypertension, and previous cardiovascular disease. All 
levels of FEV₁% impairment showed greater contrib­
utions to mortality than did hypertension, suggesting 
that the effect is independent of the thresholds used. 
Furthermore, reduced FEV₁% was second only to 
hypertension in terms of its contribution to incident 
cardiovascular disease events, suggesting that FEV₁% 
impairment is an important and under­recognised risk 
factor that contributes substantially to the global burden 
of cardiovascular disease.
In stratified analyses, for similar levels of FEV₁%, low 
country income, rural community setting, and solid­fuel 
cooking were associated with increased mortality due to 
factors independent of FEV₁%. Added to this was a 
consistent and graded increase in mortality with lower 
baseline FEV₁%. The consistency of this relationship 
across populations from diverse socioeconomic and 
geographical backgrounds, with different risk exposures 
and aetiological factors for lung function impairment, 
strongly suggests a direct causal relationship. This notion 
is further supported by the dose–response and temporal 
relationships between reduced FEV₁% at baseline and 
follow­up health outcomes, which, in keeping with Hill’s 
criteria, are suggestive of underlying causality.28 The 
same pattern was observed in low­risk subgroups, such 
as non­tobacco users, young partici pants (<50 years of 
age), and healthy participants, where the effects of 
confounders such as tobacco, senescence, and subclinical 
cardiorespiratory disease are minimised. Therefore, a 
simple measure of reduced FEV₁ across populations 
might be a feasible and informative marker for the 
population health burden, even in low­resource settings.
Another notable finding was the independent and 
additive effect of reduced FEV₁% on the elevated risk 
associated with pre­existing cardiovascular disease at 
baseline. A 2016 study showed that the prevalence of 
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obstructive lung function impairment was increased 
among people with cardiovascular disease.29 Patients 
with both cardio vascular disease and obstructive lung 
function impairment had increased incidence of 
cardiorespiratory symptoms, emergency room visits, and 
poorer health status compared with patients with 
cardiovascular disease only. Our data complement 
these findings, showing that reduced FEV₁% is an 
independent risk factor associated with a two­fold 
increase in mortality above the elevated mortality risk 
conferred by cardiovascular disease alone. Thus, reduced 
FEV₁ concomitant with cardiovascular disease has 
prognostic implications for mortality and morbidity. We 
also observed a larger effect of reduced FEV₁% in 
participants with physician­diagnosed chronic respiratory 
disease or current respiratory symptoms, suggesting a 
greater prognostic effect of reduced FEV₁% in these 
subgroups. However, existing symptoms or chronic 
respiratory disease alone—without FEV₁% impairment—
were not associated with increased future risk of 
mortality, suggesting that these clinical features per se 
have no prognostic implications. This finding reaffirms 
the need for lung function assessments in those 
suspected of having chronic respiratory disease, as 
recommended by international guidelines.5
Our study had several limitations. First, because FEV₁ 
was measured by use of a portable spirometer that did 
not provide spirographs, individual effort could not 
be verified. However, we had previously validated our 
method by comparing data obtained from hospital­based 
pulmonary function laboratories with field data in 
531 participants from the 17 participating countries, 
which showed strong agreement without biases in the 
FEV₁.10 The consistency of our findings in different 
settings also adds to the validation of these measurements 
and the practical value of spirometry assessments for 
epidemiological purposes, even in low­resource settings. 
Second, we used internally validated methodology for the 
adjustment and standardisation of lung function by 
height, age, and sex within and across populations.10 This 
practice was necessary because there was no single set of 
commonly used reference values that was able to cover 
the scope of ethnic and geographical regions in PURE. 
The GLI multiethnic reference equations provide the 
most widely endorsed reference values for four major 
ethnic groups,12 but are poorly representative for 
populations from south Asia, South America, sub­
Saharan Africa, and Malaysia, which collectively con­
tributed 40% of the PURE study population. GLI offers 
an “other” category for all other ethnic groups, but 
requires extrapolation of values that are not well matched 
by geographical region or ethnic background for these 
populations. Nevertheless, GLI­standardised FEV₁% 
values showed a pattern of association with mortality, 
cardiovascular disease, and respiratory hospitalisations 
similar to, albeit less strong than, that of PURE country­
standardised values, suggesting that our approach is 
valid, and potentially better, for predicting outcomes 
because it is customised by country.
The strengths of our study include its large sample 
size, inclusion of populations from diverse settings, and 
the prospective and standardised approach to data 
collection, outcome ascertainment, and adjustments for 
a large number of confounders.
In summary, we showed a significant and graded 
relationship between lower baseline country­standardised 
FEV₁% and future risk of mortality and cardiorespiratory 
morbidity. Addressing mild reductions in lung function 
could have a substantial effect on the population burden of 
cardiorespiratory diseases, particularly in high­risk groups 
such as tobacco users, people with known cardio vascular 
disease, and those living in poorly resourced settings. 
Further studies are also needed to examine how routine 
lung function measurement can help to better inform on 
the overall risk for poor general health outcomes.  
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